Jacob Glanville
Jacob Glanville is the CEO and President of Centivax, a biotechnology company based in San Francisco. He is known for his work in the field of immunology and infectious diseases, focusing on the development of vaccines and therapeutic strategies. Glanville recently commented on the significance of Zoetis’ bird flu vaccine, emphasizing its potential to control avian influenza outbreaks and protect the agricultural economy, highlighting the urgent need for effective vaccination strategies in livestock.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 7.00 | 0.03% | +0% | 331,002,651 | 101,348 | $21,000,000 | 6,430$ |
| Totals | 1 | 331,002,651 | 101,348 | $21,000,000 | 6,430$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Dr. Jacob Glanville, CEO of Centivax, emphasized the importance of the study on mRNA vaccines.
7
Liechtenstein:
Jacob Glanville reached out to Tim Friede to collaborate on research involving snake venom immunity.
7
Taiwan:
Jacob Glanville turned his attention towards antivenom and collaborated with Tim Friede on the research.
7
Paraguay:
Jacob Glanville is an immunologist who contacted Tim Friede to collaborate on research related to snake venom immunity.
7
United States:
Dr. Jacob Glanville said vaccines and most generic drugs would not likely be changed by the executive order.
5
Saudi Arabia:
Jacob Glanville is the founder of a vaccine development company and collaborated with Freddy on the research.
7
Turkey:
Jacob Glanville recognized Tim Friede's unusual experiments and sought to develop a universal antivenom based on his immune response.
7
Hungary:
Jacob Glanville identified two antibodies in Friede's blood that can neutralize snake venom.
8
United States:
Jacob Glanville is the lead study author and CEO of Centivax, who decided to study Tim Friede's blood for antivenom development.
8
Bolivia:
Jacob Glanville is the CEO of Centivax and is researching the potential of Tim Friede's blood as an antidote.
8